

<b>Form PTO-1449</b>		<b>U.S. Department of Commerce Patent and Trademark Office</b>				<b>Atty. Docket No.</b> <b>55099-A-PCT-</b> <b>US/JPW/AJM/AJD</b>	<b>Serial No.</b> <b>09/664,485</b>			
<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)						<b>Applicant(s)</b> Ilya Trakht				
						<b>Filing Date</b> September 18, 2000	<b>Group Art Unit</b> 1648			
<b>U.S. PATENT DOCUMENTS</b>										
<b>Examiner Initials</b>	<b>Exh. No.</b>	<b>Document Number</b>			<b>Date</b>	<b>Name</b>	<b>Class</b>	<b>Subclass</b>	<b>Filing Date If Appropriate</b>	
<b>FOREIGN PATENT DOCUMENTS</b>										
		<b>Document Number</b>			<b>Date</b>	<b>Country</b>	<b>Class</b>	<b>Subclass</b>	<b>Translation</b>	
									<b>Yes</b>	<b>No</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>										
	1	Brodin T., Olsson L., Sjorgen H. (1983) Cloning of human hybridoma, myeloma, and lymphoma cell lines using enriched human monocytes as feeder layer, J. Immunol. Meth. 60: 1-7;								
	2	Goldman-Leikin, R.E., Salawen, H.R., Herst, C.V., Variakojis, D., Bian, M.L., Le Beau, M.M., Selvanayagen, P., Marder R., Anderson, R., Weitzman, S., Rosen, S.T. (1989) Characterization of a novel myeloma line MM-I, J. Lab. Clin. Med. 113: 335-345;								
	3	Kozbor, D., Roder, J.C. (1981) Requirements for the establishment of high titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique, J. Immunol. 127: 1275-1280;								
	4	Kozbor, D., Tripputi, P., Roder, J.C., Croce, C.M. (1984) A human hybrid myeloma for production of human monoclonal antibodies, J. Immunol. 133: 3001-3005								
	5	Levy, R., Miller, R.A. (1983) Tumor therapy with monoclonal antibodies, Fed. Proc. 42: 2650-2656;								
	6	Nilsson, K., Ponten, J. (1975) Classification and biological nature of established human hematopoietic cell lines, Int. J. Cancer 15: 321-341;								
	7	Oestberg, L., Pursch, E. (1983) Human x (mouse x human) hybridomas stably producing human antibodies, Hybridoma 2: 361-367;								
	8	Posner, M.R., Schlossman, S.F., Lazarus, H. (1983) Novel approach to the construction of human "myeloma analogues" for the production of human monoclonal antibodies, Hybridoma 2: 369-381;								
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>						
<p>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>										

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 55099-A-PCT- US/JPW/AJM/AJD	Serial No. 09/664,485			
						Applicant(s) Ilya Trakht				
						Filing Date September 18, 2000	Group Art Unit 1648			
<b>U.S. PATENT DOCUMENTS</b>										
Examiner Initials	Exh. No.	Document Number			Date	Name	Class	Subclass	Filing Date If Appropriate	
<b>FOREIGN PATENT DOCUMENTS</b>								Translation		
		Document Number			Date	Country	Class	Subclass	Yes	No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>										
	9	Reading, C.L. (1982) Theory and methods for immunization in culture and monoclonal antibody production, J. Immunol. 53: 261-291;								
	10	Raison, R.L., Walker, K.Z., Halnan, C.R.E., Briscoe, D., Basten, A. (1982) Loss of secretion in mouse-human hybrids need not be due to the loss of a structural gene, J. Exp. Med. 156: 1380-1389;								
	11	Teng, N.N.H., Lam, K.S., Riera, F.C., Kaplan, H.S. (1993) Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production, Proc. Natl. Acad. Sci. (U.S.A.) 80: 7308-7311; and								
	12	Weiss, M.C., Green, H. (1967) Human mouse hybrid cell lines containing partial complements of human chromosomes and functioning human genes, Proc. Natl. Acad. Sci. (U.S.A.) 58: 1104-1111.								
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>						
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>										